PartnershipJul 22, 2026, 08:36 AM
bioAffinity Technologies Partners with Pictor for Asthma/COPD Diagnostics
AI Summary
bioAffinity Technologies, Inc. announced a collaboration with Pictor, Inc. to develop and commercialize next-generation diagnostic tests for lung inflammation in patients with asthma and chronic obstructive pulmonary disease (COPD). This partnership aims to integrate bioAffinity's expertise in flow cytometry with Pictor's targeted proteomic analysis platform to enhance laboratory efficiency, reduce costs, and provide more personalized treatment insights. The tests, building on bioAffinity's proprietary sputum analysis approach, are designed to help physicians match patients with more effective and targeted therapies, addressing a global therapeutics market projected to exceed $108 billion in 2026.
Key Highlights
- bioAffinity Technologies partnered with Pictor, Inc. for next-generation asthma and COPD diagnostic tests.
- Collaboration integrates bioAffinity's flow cytometry with Pictor's targeted proteomic platform.
- Aims to lower operating costs and improve laboratory efficiency for high-throughput testing.
- Tests designed to provide a complete picture of lung inflammation for personalized treatment.
- Global asthma and COPD therapeutics market projected to exceed $108 billion in 2026.
- Market is projected to reach $155 billion by 2030.
- bioAffinity will own intellectual property associated with the new tests.
- Tests will initially be offered as Laboratory Developed Tests (LDTs) under CLIA.
Price Impact
More from BIAF